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Background: Many drugs are substrates for P-glycoprotein (P-gp) and interactions involving P-gp may be relevant
to clinical practice. Co-administration with P-gp inhibitors or inducers changes the absorption profile as well as the
risk for drug toxicity, therefore it is important to evaluate possible P-gp alterations. The purpose of this study was to
investigate the effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP)
and nanostructured aluminium silicate (NSAS), a protonated montmorillonite clay, on mdr-1 gene expression and its
protein, P-glycoprotein (P-gp) within Caco-2 cells.
Methods: The effects of DAPP and NSAS on the regulation of mdr-1 gene, P-gp protein expression and activity
within Caco-2 cells, were determined using cell viability and cytotoxicity tests, RT-PCR, Western Blot analysis and
bi-directional transport studies.
Results: We observed a significant down-regulation of mdr-1 mRNA (e.g. 38.5 ± 17% decrease vs. control at 5 μM
DAPP and 61.2 ± 25% versus control at 10 μM DAPP; n = 6, P* < 0.05) within Caco-2 cells. Western Blot analysis of
P-gp expression showed that changes in mdr-1 gene expression lead to correlating changes in P-gp protein
expression. This down-regulation of P-glycoprotein also resulted in decreased activity of P-glycoprotein compared
to untreated control. In contrast, when Caco-2 cells were treated with NSAS, no changes in mdr-1 gene expression,
P-gp protein expression nor P-gp activity were observed.
Conclusions: DAPP but not NSAS decreases P-gp mediated drug efflux through decreased mdr-1 gene expression
and consequently decreased P-gp protein expression. These findings have to be taken into consideration when
DAPP is concurrently given with other drugs that are substrates for P-gp since drug-drug interactions harbour a
safety issue and alter bioavailability profiles.
NSAS does not have any P-gp altering properties and therefore might not affect drug-drug interactions. We conclude
from this study that NSAS might make a safer drug candidate compared to DAPP for lowering LDL-cholesterol.* Correspondence: Kishor.Wasan@usask.ca
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It has been estimated that by 2030 the number of deaths
due to Cardiovascular disease (CVD) will climb to 23.3
million and CVD will remain the single leading cause of
death [1]. The World Health Organization recommends
increased government investment in prevention and early
detection through national programs that are aimed
to prevent and control non-communicable diseases
like CVD. The application of new research findings
towards new and better treatments, personalized medical
care and interventions as well as the implementation of
updated and improved guidelines are necessary for better
outcomes for patients.
Substantial scientific evidence highlights elevated
cholesterol levels as a risk factor for coronary artery
disease. Despite much clinical success, statins are not well
tolerated by all patients. Sufficient LDL-cholesterol lowering
cannot be achieved by statin monotherapy in every patient
[2-4] and reduction of cardiovascular events can only be
reduced by 33% in the most responsive patients [5].
In about 2-10% of patients on statins the side effects
are very severe and therefore the statin therapy has to
be discontinued and replaced with alternative therapies [6].
An alternative approach to decreasing LDL-cholesterol is
inhibiting the absorption of dietary cholesterol using plant
sterols and plant stanols (phytosterols and phytostanols),
either as as dietary supplements or as additives in food
products including margarine, cereals, juices and yogurt
[7]. The ability of plant sterols to reduce serum cholesterol
levels has been known since the 1920s and was confirmed
by studies in animals and humans in the 1950s [8-10].
Despite considerable research, the mechanism by which
they reduce cholesterol is a topic of debate. Phytosterols
are poorly absorbed in the intestines (between 0.4%
and 3.5%), and as with cholesterol, they are poorly
water soluble [11].
One explanation is that phytosterols compete with
cholesterol for being incorporated into mixed micelles
which are made of dietary fat, bile acids and sterols.
Cholesterol not incorporated into the micelle phase is
unable to cross the unstirred water layer that lines theFigure 1 Chemical structure of DAPP. The two major components of DA
ascorbyl sitostanol phosphate, each covalently linked to ascorbic acid by aintestinal wall and cannot be taken up by the enterocytes
for subsequent packaging into chylomicrons. Other studies
are suggestive of alternate mechanisms contributing to their
LDL-cholesterol lowering characteristics. Kaneko et al. have
proposed that phytosterols might function as agonists
for the liver X receptor (LXR). LXR is a nuclear receptor
responsible for upregulating cholesterol efflux pathways
throughout the body [12]. Additionally, suppression of
de novo cholesterol synthesis has been shown in a rat
model [13].
Phytosterols can be modified to increase their micellar
incorporation capacity by esterification with fatty acids
and many different modified phytosterols have been tested
for activity. One such well characterized phytosterol is
disodium ascorbyl phytostanol phosphate (DAPP), also
known as FM-VP4 (Figure 1). It is a water-soluble
derivative of sitostanol and campestanol linked by
esterification with an ascorbyl-phosphate group [14,15].
In animal studies with rats, gerbils and mice FM-VP4
effectively reduces dietary cholesterol absorption [16,17].
This cholesterol lowering effect also leads to a reduction
of atherosclerotic lesion formation in apo E knockout
mice, a model that represents atherosclerosis [18].
FM-VP4 has also shown a decrease in body mass
without any toxic effects [19]. This dose dependent
reduction of mass in mice treated with FM-VP4 was not
due to an increase in resting metabolic rate or decreased
food or water intake, but through decreased absorption or
increased excretion of lipids.
Potent cholesterol-lowering characteristics without any
significant toxic effects was also shown in preclinical
and clinical studies [15,16]. A clinical study in 30 men
demonstrated that up to 800 mg/day of DAPP is safe
and well tolerated for at least 4 weeks. LDL-cholesterol
was significantly reduced by 6.6% (p = 0.02) in the 400 mg
per day group [20].
Another compound of interest is nanostructured
aluminosilicate (NSAS). NSAS is a protonated montmoril-
lonite (bentonite) clay. Bentonites are naturally occurring
compounds and recent studies have demonstrated choles-
terol lowering effects and define them as a new class ofPP are disodium ascorbyl campestanol phosphate and disodium
phosphodiester bond [14,15].
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absorption of cholesterol by 39%, similar to an identical
dose of stigmasterol, by competing with cholesterol for
absorption in the intestine after ingestion [21]. The first
reported medical use of bentonite clay goes back to
ancient Mesopotamia where it was applied externally
as a mud bath and was touted for anti-inflammatory
and antiseptic characteristics.
NSAS is composed of layers of aluminium octahedral
sheets sandwiched between two silicon-oxygen tetrahedral
layers (Figure 2). NSAS has a high surface area
(200-800 m2/g) and shows high water and organic material
absorption characteristics either by adsorption onto its
external surface or into its interlaminar space. It is
negatively charged in contrast to positively charged bile
acids and surface protons are incorporated to counterbal-
ance platelet surface negative charge [22]. Additionally,
NSAS appears relatively safe for oral administration and is
minimally absorbed.Figure 2 Structure of montmorillonite clay. Montmorillonite has a layer
enclosing a sheet of octahedral aluminium crystals. Water and surface cationsOral administration of NSAS significantly inhibits chol-
esterol absorption in mice. Apo E knockout mice fed a diet
high in cholesterol and fat were treated for 12 weeks with
NSAS (1.4% w/w) or stigmastanol (2% w/w) and showed
significant reductions in plasma cholesterol concentrations
relative to control animals in both groups. No changes in
food and water intake or body weight were observed.
Atherosclerotic lesion formation at the aortic root
was also reduced [23]. In vitro lipolysis studies adapted to
stimulate intraluminal processing of triglycerides and
cholesterol in the presence of NSAS showed an inhibition
of cholesterol absorption either by direct binding to
cholesterol or by other mechanisms like incorporation
into micelles. Protonated NSAS adsorbs and sequesters
cholesterol from the aqueous phase in the digestive tract
resulting in precipitation and excretion with feces [24].
Potent inhibition of cholesterol absorption and minimal
systemic exposure make NSAS a considerable candidate
for treatment of hypercholesterolemia, either as adjunctive-lattice structure consisting of two sheets of tetrahedral siliconcrystals
enter between adjacent silicon sheets causing the material to expand.
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to tolerate statins.
Most cardiovascular patients require multiple medications
in addition to lipid lowering therapy, creating the possibility
for drug interactions. Many of these drugs are substrates for
P-glycoprotein (P-gp), which mitigates cellular exposure to
various hydrophobic compounds thereby protecting
cells from xenobiotics and other potential toxins. P-gp is
expressed in numerous tissues including the small intestine,
blood–brain barrier, hepatocytes, and kidney proximal
tubule which affects intracellular and systemic drug
concentrations; therefore, it is important to understand
the behaviour of new drugs and therapies in regards to
modification of P-gp.
P-gp belongs to the ATP-binding cassette (ABC)
superfamily, which in humans, consists of several
hundred transmembrane transport proteins which belong
to 7 distinct subfamilies named ABCA – ABCG. They
import and export a broad variety of substrates across
cellular membranes including amino acids, lipids, drugs,
and proteins. ABC genes are essential for many processes
in the cell and mutations cause or contribute to several
genetic disorders such as cystic fibrosis, neurological
disease, retinal degeneration, Stargardt disease, cholesterol
and bile transport defects, anemia, and abnormal drug
responses). P-gp was the first identified human ABC trans-
porter gene [25] and was first described in drug-resistant
cells with a defined pattern of multidrug resistance
[26]. P-gp relies on ATP as an energy source for drug
efflux. Humans have two multidrug resistance (mdr)
genes mdr-1 and mdr-2 (also called mdr-3), whereas
rodents have three mdr genes mdr-1A (also called
mdr-3), mdr-1B (also called mdr-1) and mdr-2. Only
mdr-1 in humans and mdr-1A & B in rodents are involved
in drug transport and drug-resistance [27,28]. Expression
of P-gp in intestinal epithelial cells is responsible for efflux
that limits cellular uptake into enterocytes and drug
absorption. Drugs can be defined as P-gp inhibitors, P-gp
enhancers or P-gp substrates. P-gp inhibitors impair P-gp
mediated efflux while inducers enhance P-gp activity.
A multitude of drugs, including several with a narrow
therapeutic index, interact with P-gp and drug-drug
interactions must be considered given their impact on
bioavailability and therapeutic outcome. Hence, the FDA
now advises drug developers to characterize interactions
between new drugs and P-gp, as stated in guidelines
released in 2012 concerning drug-drug interactions. This
just signifies the importance for evaluating P-gp interac-
tions during novel drug development and to recommend
clinical guidelines for clinicians when administering P-gp
substrate drugs.
We studied the in vitro interactions between two novel
cholesterol lowering agents, DAPP and NSAS, and the
P-gp transporter protein using Caco-2 cells.Materials and methods
Materials
NSAS was provided by AMCOL International Corporation
(Chicago, USA). Triton X-100, Tween-80, HEPES, Protease
inhibitor cocktail, Na-deoxycholate, EDTA and NaCl were
obtained from Sigma-Aldrich (St. Louis, MO, USA).
All tissue culture reagents were from Invitrogen/Life
Technologies (Grand Island, NY, USA). T-75 flasks,
tissue culture treated plates and Transwell® inserts
were from Corning Incorporated (Corning, NY, USA).
CytoTox96® Non-Radioactive Cytotoxicity Assay, MTS
CellTiter 96® AQueous One Solution Cell Proliferation Assay
and Pgp-GloTM Assay were from Promega Corporation
(Madison, WI, USA). BCATM Protein Assay Kit was
obtained from Pierce Biotechnology, Inc. (Rockford, IL,
USA). NP-40 was purchased from Roche Applied Science
and Trans-Blot® Transfer medium (nitrocellulose membrane
0.45 μM) from Bio-Rad (Hercules, CA, USA).
Methods
Cell culture
Caco-2, human colon adenocarcinoma cells, were pur-
chased from ATCC (Rockville, MD, USA) and passage
numbers between 20 and 35 were used. Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal bovine solution (FBS),
292 μg mL−1 L-glutamine, 0.1 mM non-essential amino
acids, 100 U/mL penicillin and 100 μg/mL streptomycin
containing 1.5 g/L NaHCO3 at 37°C in humidified air con-
taining 5% CO2. Stock cultures were grown in T-75 flasks.
Once the cells reached a confluency of about 90%, they
were then split by using 0.25% trypsin containing 1.0 mM
EDTA. Cells were seeded in 96-well, 48-well, 12-well, or
Transwell plates depending on the type of experiment.
The medium was changed every other day.
Cytotoxicity measurements
To determine non-cytotoxic concentrations, the following
markers of toxicity were employed: 1) cell plasma
membrane integrity as determined by lactate dehydrogenase
(LDH) release and 2) mitochondrial respiration as
measured by the reduction of a tetrazolium compound
(MTS) to a soluble formazan product. Caco-2 cells were
seeded onto 96-well plates and were kept at 37°C in
humidified air containing 5% CO2 until the cells reached
90% confluency. On the day of the experiment, the culture
medium was exchanged for treatment solutions of 0 to
1000 μg/mL NSAS or 0 to 500 μM DAPP and 1% Triton
X-100 (as positive control for cytotoxicity) in Hanks’
Balanced Salt Solution without phenol (HBSS) containing
10 mM HEPES, pH 7.4. LDH release (CytoTox96®
Non-Radioactive Cytotoxicity Assay), MTS reduction
(CellTiter 96® AQueous One Solution Cell proliferation
Assay) and bicinchoninic acid (BCATM Protein Assay Kit)
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lated relative to the 100% control (MTS-Assay). Cytoxicity
was calculated relative to 100% cytotoxicity obtained from
the Triton X-100 group (LDH-Assay).
Protein expression: western blotting
Protein levels were qualitatively observed by Western
blot techniques. Caco-2 cells were treated with culture
medium (control) or culture medium containing non-
cytotoxic concentrations of NSAS or DAPP. Cells
were washed three times with PBS and harvested with
RIPA lysis buffer (50 mM HEPES, 150 mM NaCl,
2 mM EDTA, 0.5% Na-deoxycholate, 1% NP-40) containing
protease inhibitor cocktail (1:100 dilution). Protein content
was determined by BCA protein assay and the cell
membrane proteins (20 μg/lane) were separated by
electrophoresis through a 10% SDS-polyacrylamide gel
and then electroblotted onto a nitrocellulose membrane.
A pre-stained protein standard from Bio-Rad was used to
identify the P-gp protein band at 170kD and actin at
42kD. The membrane was incubated overnight at 4°C in
blocking buffer (1 × PBS, 2.5% nonfat dried milk, 0.1%
Tween-20), and probed with a 1:300 dilution of primary
antibody (C219 from Signet Pathology System Dedlam) to
detect P-gp and a 1:1000 dilution of I-19 (Santa Cruz
Biotechnology) to detect actin as an internal control. The
membranes were washed 3 times with PBS and 1%
Tween-20 (PBS-T) and the membrane was incubated
in a 1:5000 dilution of anti-mouse IgG rabbit horse-
radish peroxidase (HRP)-conjugated antibody (Jackson
ImmunoResearch Laboratories) and a 1:3000 dilution
of anti-goat IRP bovine HRP (Santa Cruz Biotechnology)
for P-gp and Actin respectively. Three washing steps with
PBS-T followed. Bands were visualized with ECL and
quantified with Labworks software (UVP).
RNA-isolation and RT-PCR
Caco-2 cells were harvested and total RNA was isolated
with TRIzol® Reagent (Invitrogen) according to the man-
ufactures instruction. RNA was reverse transcribed into
cDNA. The concentration of cDNA reaction product was
measured by using Oligreen-Assay (Molecular Probes). The
primers were synthesized at the Oligonucleotide Synthesis
Laboratory at UBC. Parameters and conditions for the
tested primers were optimized. The following primers
were used for the described studies. Mdr-1 (5′- GTC-
ATT-GTG-GAG-AAA-GGA-AAT-CAT-G-3 and 5′- ATT-
CCA-AGG-GCT-AGA-AAC-AAT-AGT-G-3′ and GAP
DH (5′- TGA-AGG-TCG-GAG-TCA-ACG-GAT-3′ and
5′- TCG-CTC-CTG-GAA-GAT-GGT-GAT-3′). A sample
from each PCR product was subjected to electrophoresis
on a 1.5% agarose gel (containing Ethidium bromide). A
100 bp ladder was used to identify the size of PCR
products. The fluorescent bands were imaged under UVlight (UV-Epi Chemi II) and quantified with UVP-labworks
software.
Transmembrane transport of rhodamine 123
Caco-2 cells form monolayers and express P-gp on
their apical membranes thereby differentiating into a
highly functionalized epithelial barrier that is morpho-
logically and biochemically similar to small intestine col-
umnar epithelium. A good system to measure apical and
basolateral transport across monolayers and to determine
the permeability of a certain substance is a Transwell®
plate. Cells are grown on a semi-permeable membrane
which is placed between two chambers. Donor and
acceptor chambers are determined by experiment type. To
model intestinal drug absorption, the substance is given
into the apical side and the concentration in the basolateral
side is measured. Secretory transport can be determined if
the substance is added onto the basolateral side and the
concentration in the apical chamber is measured. P-gp
mediated transport is characterized by basolateral to apical
transport greater than apical to basolateral transport.
Caco-2 cells were seeded in polycarbonate membrane
Transwell® plates. at a densitiy of 40.000 cells/cm2 and
grown in a humidified chamber (at 37°C, of 5% CO2.)
with media changes every 2 days. The growth media
(Dulbecco’s minimal essential medium-DMEM) contained
10% heat-activated fetal bovine serum, 292 μg/ml glutamine,
0.1 mM non-essential amino acids, 100U/ml penicillin
and 100 mg/ml glutamine. For the treatment experiments,
NSAS or DAPP in different concentrations was added
to the media and either applied onto apical and/or the
basolateral side of the Transwell plate.
Transepithelial electrical resistance (TEER) of the mono-
layers was measured to confirm monolayer integrity with a
Millicell Electrical Resistance System (Milipore Corp.,
Bedford, MA). Caco-2 cells with TEER Values above
300 Ω · cm2 were used for transport studies. Cells
were washed 3 times with PBS before treatment solutions
were loaded on the apical side. Plates were incubated
and TEER values were measured before and after the
treatment to ensure integrity of the monolayer and
tight junctions.
Rhodamine 123 (Rh123) is a fluorescent dye and P-gp
substrate and has been used as a probe to measure
the functional activity of P-gp. It has a molar extinc-
tion coefficient of 85,200 M−1 cm−1 at 511 nm. Rh123
was added to either the apical or basolateral cham-
ber, with transport buffer in the corresponding re-
ceiver chamber. In a time dependent manner, samples
(50 μl) were collected with media replacement from
receiver chamber and transferred into a 96-well plate.
Rh123 concentrations were measured with a Fluoroskan
Ascent fluorometer (excitation = 485 nm and emission =
538 nm).
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using the following equation:
Papp ¼ dQdt C∩ ⋅
I
A
A is the area of absorption (cell monolayer), dQ/dt is
the cumulative amount of test compound appearing in
the receiver compartment of the assay system versus
time, and Co is the initial concentration of the test
compound in the donor compartment.
Statistical analysis
All data sets were analyzed for statistical significance by
parametric methods using SigmaStat version 3.5. When
comparisons were made between two groups, unpaired
two-tailed t tests were used. All data are expressed as
mean ± standard deviation.
Results
Measurement of toxicity of NSAS and DAPP in Caco-2
cells
Treatment with concentrations between 0 and 500 μg/ml
NSAS and 0 and 250 μM DAPP showed no significant
difference in cell viability compared to untreated control
as measured by MTS assay (Figures 3A and 4A). Results
from the LDH assay showed no significant cytoxicity
for concentrations between 0 and 300 μg/mL NSAS
and 0 and 100 μM DAPP compared to untreated control
(Figures 3B and 4B). These nontoxic concentrations wereFigure 3 Cell viability and cytotoxicity after treatment with NSAS. Effe
with different concentrations of NSAS for 24 hours. Results are compared to u
the mean ± SD. *p < 0.05. N = 3.subsequently used to treat cells for cholesterol uptake,
transporter protein expression, Rh123 accumulation and
transport studies across the Caco-2 cell monolayer.P-gp protein expression
No changes in protein expression for P-glycoprotein were
measured when Caco-2 cells were incubated for 24 hours
with NSAS at 10 μg/mL, 100 μg/mL, and 500 μg/mL
(Figure 5). However when Caco-2 cells were treated for the
same length of time with DAPP a significant change was
observed (Figure 6). Incubation with DAPP 10 μM leads to
a lesser expression of P-gp (41 ± 6% versus untreated
control cells). We performed PCR reactions for those tested
time points. A significant decrease in mdr-1 gene expres-
sion was observed when cells were treated with DAPP. All
data obtained for mdr-1 gene expression were normalized
for GAPDH gene concentration (Figures 5C and 6C).
In summary, down-regulation of mdr-1 gene expression
was shown, complementing the results for decreased P-gp
protein expression (38.5 ± 17% for treatment with 5 μM
DAPP and 61.2 ± 25% for treatment with 10 μMDAPP ver-
sus untreated control cells). Figure 6 shows the correlation
from a decreased gene expression into decreased protein
expression even after one week of treatment. The largest
effect was seen for a concentration of 10 μM of DAPP.Transmembrane transport of rhodamine 123
Experiments were performed to measure the activity of
P-gp in Caco-2 cells after treatment with DAPP.ct on Caco-2 cells. MTS-Assay (A) and LDH-Assay (B) after incubation
ntreated control cells (in A) and Triton X-100 (in B). Each bar represents
Figure 4 Cell viability and cytotoxicity after treatment with DAPP. Effect on Caco-2 cells. MTS-Assay (A) and LDH-Assay (B) after incubation
with different concentrations of DAPP for 24 hours. Results are compared to untreated control cells (in A) and Triton X-100 (in B). Each bar represents
the mean ± SD. *p < 0.05. N = 4.
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m-RNA (e.g. 38.5 ± 17% for treatment with 5 μM DAPP
and 61.2 ± 25% for treatment with 10 μM DAPP; n = 6,
P* < 0.05) within Caco-2 cells. Western Blot analysis of
P-glycoprotein expression showed that changes in mdr-1
gene expression lead to correlating changes in P-gp proteinFigure 5 P-gp protein expression in Caco-2 cells after treatment with
10 μg/mL, 100 μg/mL and 500 μg/mL NSAS compound A. (A) Representat
of P-gp protein normalized by the protein expression of actin. There is no stati
(C) Expression profile of mdr-1 gene expression in Caco-2 cells. A sample from
and the fluorescent bands were quantified with UVP-Labworks software. Eachexpression. This down-regulation of P-glycoprotein also
resulted in a decreased activity of P-glycoprotein compared
to untreated control.
Treatment with 5 and 10 μM DAPP resulted in a signifi-
cant increase in Rh123 accumulation by two-fold relative to
untreated control cells (Figure 7B). Accumulation of Rh123NSAS. Cells were exposed for 24 hours to media alone (control),
ive Western Blot. (B) The data represent the mean ± standard deviation
stically significant difference between treatment groups and control. N = 3.
each PCR product was subjected to electrophoresis on a 1.5% agarose gel
value represents the mean ± standard deviation of N = 3.
Figure 6 P-gp protein expression in Caco-2 cells after treatment with DAPP. Cells were exposed for 24 hours to media alone (control),
1 μM, 10 μM and 500 μM DAPP. (A) Representative Western Blot. (B) The data represent the mean ± standard deviation of P-gp protein normalized by
the protein expression of actin. *p < 0.05. N = 6. (C) Expression profile of mdr-1 gene expression in Caco-2 cells. A sample from each PCR product was
subjected to electrophoresis on a 1.5% agarose gel and the fluorescent bands were quantified with UVP-Labworks software. Each value represents the
mean ± standard deviation of N = 6. *p < 0.05.
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cells treated with the positive control for P-gp inhibition,
verapamil.
These findings suggest that DAPP not only has
cholesterol-lowering properties but also decreases P-pg
mediated drug efflux and might reverse multi-drug
resistance.
DAPP treatment lead to a statistically significant
decrease in secretory flux compared with untreated control
cells (Figure 8), while TEER values stayed unchanged.
Bentonite on the other hand had shown cholesterol
lowering characteristics without influencing transporter
proteins. Also, no changes for Rh123 accumulation
were observed (Figure 7A) when compared to untreated
control cells.Figure 7 Effect of NSAS and DAPP on Rhodamine 123 uptake in Caco
increasing concentrations of NSAS (A) or DAPP (B). Cellular accumulation o
in each well. Data is presented as mean ± standard deviation with N = 6. *pIn Summary DAPP has an influence on the expression
of mdr-1.; a decrease of the mRNA level lead to a decrease
in P-glycoprotein expression. A corresponding decreased
P-gp activity was also observed. None of those changes in
mdr-1 gene expression, P-gp protein expression and
activity were seen with NSAS.
Conclusions
Since the introduction of statins in the 1980s, they have
become a golden standard of lipid-lowering therapy. They
are prescribed for treatment of hypocholesterolemia
and to reduce LDL-cholesterol and therefore reducing
coronary artery disease-related morbidity and mortality.
Over the past years statins have been proved to be safe
and well-tolerated drugs. However there are more and-2 cells. Cells were exposed for 24 h to media alone (control), or to
f Rhodamine 123 was normalized with respect to the protein content
< 0.001 vs. control (A) and *p < 0.05 vs. control (B).
Figure 8 Effect of pre-incubation with DAPP on P-gp transport of Rhodamine 123 across Caco-2 cell monolayer (basolateral to apical
transport) and apparent Permeability Papp. Data represent the average of N = 6 ± SD. *p < 0.025. TEER values were measured before and after the
treatment and at the end of the experiment. No changes in TEER values were seen which indicates the integrity of the monolayers. Treatment with
DAPP lead to a statistically significant decrease in secretory flux compared with untreated control cells. Treatment with Verapamil represents a positive
control for P-gp inhibition.
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to statin treatment or experience minor to severe adverse
reactions. The need for new and alternative therapies
is more present and prominent. Studies of either new
pharmacological agents or treatments in combination
with established therapies are under way.
The study here investigates the effect on P-gp expression
and activity of two substances, DAPP and NSAS, of the
new class of cholesterol lowering agents.
This is of relevance for drug toxicity and efficacy since
most patients take several medications simultaneously
and many of the commonly prescribed drugs are
substrates for P-gp. Drugs with narrow therapeutic
indexes have shown large increases in concentration
when co-administred with potent P-gp inhibitors or
when the drug itself functions as P-gp inhibitor.
In previously published studies both agents (DAPP and
NSAS) have shown a significant decrease in cholesterol
absorption. This was tested in different models and
no severe side effects were observed.
We found that unlike DAPP, NSAS did not change
P-gp expression in our Caco-2 cell model. From that
perspective NSAS may be a safer candidate for cholesterol-
lowering treatment with regards to drug-drug interactions
and adverse effects. Given our observation, DAPP has
the potential to modulate P-gp mediated drug transport.
Phytostanols and phytosterols have been widely used asadditives to cereals, margarine, drinks and other food
sources or are given as supplements to reduce serum
cholesterol levels. Given the new findings of lowering
P-gp protein expression and activity, this observation
raises the possibility that when administered with other
drugs, it might impact their uptake, bioavailability, and the
therapeutic outcomes.
There are several limitations to this work and fur-
ther studies are required to determine between these
two agents and other ABC transporter proteins.
Though P-gp is the most significant one, there are
several other transporter proteins which may impact
drug absorption such as multidrug resistance associ-
ated protein (MRP), breast cancer resistance protein
(BCRP), organic anion transporter (OAT), organic anion
transporting polypeptide (OATP), organic cation trans-
porter (OCT) and oligopeptide transporter (PEPT).
Additionally, these findings need to be confirmed in an
animal model to evaluate clinical significance of our
findings.
Data presented here further substantiate the need for
addressing and investigating potential transporter protein
interactions when developing new drug therapies.
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